Imaging genetic influences in human brain function

Current Opinion in Neurobiology

Volumn 14, Issue 2, 2004, Pages 239-247

  Mattay, Venkata S ^a   Goldberg, Terry E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT; 5 HTT; AD; Alzheimer's disease; APOE; Apolipoprotein E; BDNF; Blood oxygenation level dependent functional magnetic resonance imaging; BOLD fMRI; Brain derived neurotrophic factor; Catechol O methyl transferase; COMT; DA; Serotonin; Serotonin transporter

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMPHETAMINE; APOLIPOPROTEIN E4; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE 4 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; OPIATE RECEPTOR; SEROTONIN; SEROTONIN TRANSPORTER;

AMYGDALOID NUCLEUS; ANXIETY; BEHAVIOR; BRAIN FUNCTION; BRAIN NERVE CELL; CATECHOLAMINERGIC SYSTEM; CHOLINERGIC SYSTEM; COGNITION; DOPAMINE RELEASE; FEAR; GENE MUTATION; GENETIC PROCEDURES; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; HEREDITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; INTERNEURON; MEMORY; MEMORY DISORDER; MENTAL DISEASE; MENTAL TASK; NEUROCHEMISTRY; NEUROIMAGING; NEUROPHYSIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STIMULUS RESPONSE;

APOLIPOPROTEINS E; BIOGENIC MONOAMINES; BRAIN; BRAIN CHEMISTRY; BRAIN MAPPING; BRAIN-DERIVED NEUROTROPHIC FACTOR; DIAGNOSTIC IMAGING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 1842684454     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.conb.2004.03.014     Document Type: Review

References (53)

1. Krubitzer L., Kahn D.M. Nature versus nurture revisited: an old idea with a new twist. Prog Neurobiol. 70:2003;33-52.
2. Malhotra A.K., Goldman D. Benefits and pitfalls encountered in psychiatric genetic association studies. Biol Psychiatry. 45:1999;544-550.
3. Glatt C.E., Freimer N.B. Association analysis of candidate genes for neuropsychiatric disease: the perpetual campaign. Trends Genet. 18:2002;307-312.
4. Hariri A.R., Weinberger D.R. Imaging genomics. Br Med Bull. 65:2003;259-270.
5. ••] . Using BOLD fMRI while subjects perform a simple declarative memory task they demonstrated that an interaction of genotype and BOLD response during encoding was a strong predictor of behavioral accuracy.
6. Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 14:2001;21-36.
7. Moseley M., Bammer R., Illes J. Diffusion-tensor imaging of cognitive performance. Brain Cogn. 50:2002;396-413.
8. Gonzalez-Burgos G., Kroner S., Krimer L.S., Seamans J.K., Urban N.N., Henze D.A., Lewis D.A., Barrionuevo G. Dopamine modulation of neuronal function in the monkey prefrontal cortex. Physiol Behav. 77:2002;537-543.
9. Seamans J.K., Durstewitz D., Christie B.R., Stevens C.F., Sejnowski T.J. Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci U S A. 98:2001;301-306.
10. Goldman-Rakic P.S., Muly E.C. III, Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 31:2000;295-301.
11. Lewis D.A., Melchitzky D.S., Sesack S.R., Whitehead R.E., Auh S., Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol. 432:2001;119-136.
12. Mazei M.S., Pluto C.P., Kirkbride B., Pehek E.A. Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res. 936:2002;58-67.
13. Moron J.A., Brockington A., Wise R.A., Rocha B.A., Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 22:2002;389-395.
14. Mannisto P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev. 51:1999;593-628.
15. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 98:2001;6917-6922.
16. Malhotra A.K., Kestler L.J., Mazzanti C., Bates J.A., Goldberg T., Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry. 159:2002;652-654.
17. Joober R., Gauthier J., Lal S., Bloom D., Lalonde P., Rouleau G., Benkelfat C., Labelle A. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry. 59:2002;662-663.
18. Goldberg T.E., Egan M.F., Gscheidle T., Coppola R., Weickert T., Kolachana B.S., Goldman D., Weinberger D.R. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 60:2003;889-896.
19. Mattay V.S., Goldberg T.E., Fera F., Hariri A.R., Tessitore A., Egan M.F., Kolachana B., Callicott J.H., Weinberger D.R. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A. 100:2003;6186-6191 In this study, the authors explore the neural underpinnings related to individual differences in the brain response to stimulants like amphetamine. To this end, they investigate the effects of the COMT val-met polymorphism on the actions of amphetamine in prefrontal cortex. Subjects were given either amphetamine or placebo and imaged with BOLD fMRI while performing a task with increasing working memory load in a double-blind counter balanced study. Consistent with basic evidence that dopamine impacts prefrontal function in an inverted 'U' shaped curve, they demonstrate that amphetamine improves the efficiency of prefrontal function in individuals homozygous for the val allele (who presumably have lower dopaminergic tone at baseline). On the other hand, they illustrate a detriment in the efficiency of PFC function in individuals homozygous for the met allele (who presumably have a higher dopaminergic tone at baseline relative to the val homozygotes) only at higher working memory loads. This probably reflects increased dopaminergic signaling from the combined effects of amphetamine and increased stress (for example, in situations requiring higher cognitive demands), that pushes these individuals beyond a critical threshold on the inverted 'U' curve of dopamine at which compensation can be made.
20. 11 carfentanil, a μ-opioid receptor selective radiotracer, the authors demonstrate that varying levels of catecholamine metabolism conferred by the COMT val-met polymorphism are associated with downstream alterations in the functional responses of the μ-opioid neurotransmitter system and compensatory changes in u-opioid receptor binding in the striatopallidal circuits, the thalamus, the amygdala and the anterior cingulate. Specifically, they observed that met homozygotes showed a diminished μ-opioid response in these regions to pain when compared to the val-met heterozygotes.
21. Yang C.R., Seamans J.K. Dopamine D1 receptor actions in layers V-VI rat prefrontal cortex neurons in vitro: modulation of dendritic-somatic signal integration. J Neurosci. 16:1996;1922-1935.
22. Seamans J., Gorelova N., Durstewitz D., Yang C. Bidirectional regulation of GABAergic inhibition in the prefrontal cortex by dopamine. J Neurosci. 21:2001;3628-3638.
23. Law-Tho D., Hirsch J.C., Crepel F. Dopamine modulation of synaptic transmission in rat prefrontal cortex: an in vitro electrophysiological study. Neurosci Res. 21:1994;151-160.
24. Fan J., Fossella J., Sommer T., Wu Y., Posner M.I. Mapping the genetic variation of executive attention onto brain activity. Proc Natl Acad Sci U S A. 100:2003;7406-7411 The authors examine whether or not previously reported associations between polymorphisms in DRD4 and MAO-A genes and efficiency of handling conflict, as measured by differences in reaction time, might contribute to differences in activation in the anterior cingulate across individuals. They report that alleles in these two genes that were associated with better performance showed more activation in comparison to the alleles associated with worse performance.
25. Rypma B., D'Esposito M. Isolating the neural mechanisms of age-related changes in human working memory. Nat Neurosci. 3:2000;509-515.
26. Mattay V.S., Tessitore A., Callicott J.H., Bertolino A., Goldberg T.E., Chase T.N., Hyde T.M., Weinberger D.R. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol. 51:2002;156-164.
27. Hariri A.R., Weinberger D.R. Functional neuroimaging of genetic variation of serotonergic neurotransmission. Genes Brain Behav. 2:2003;341-349.
28. Ball D., Hill L., Freeman B., Eley T.C., Strelau J., Riemann R., Spinath F.M., Angleitner A., Plomin R. The serotonin transporter gene and peer-rated neuroticism. Neuroreport. 8:1997;1301-1304.
29. Ebstein R.P., Segman R., Benjamin J., Osher Y., Nemanov L., Belmaker R.H. 5-HT2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet. 74:1997;65-72.
30. Katsuragi S., Kunugi H., Sano A., Tsutsumi T., Isogawa K., Nanko S., Akiyoshi J. Association between serotonin transporter gene polymorphism and anxiety-related traits. Biol Psychiatry. 45:1999;368-370.
31. Flory J.D., Manuck S.B., Ferrell R.E., Dent K.M., Peters D.G., Muldoon M.F. Neuroticism is not associated with the serotonin transporter (5-HTTLPR) polymorphism. Mol Psychiatry. 4:1999;93-96.
32. Deary I.J., Battersby S., Whiteman M.C., Connor J.M., Fowkes F.G., Harmar A. Neuroticism and polymorphisms in the serotonin transporter gene. Psychol Med. 29:1999;735-739.
33. Jacobsen L.K., Staley J.K., Malison R.T., Zoghbi S.S., Seibyl J.P., Kosten T.R., Innis R.B. Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. Am J Psychiatry. 157:2000;1134-1140.
34. Hariri A.R., Mattay V.S., Tessitore A., Kolachana B., Fera F., Goldman D., Egan M.F., Weinberger D.R. Serotonin transporter genetic variation and the response of the human amygdala. Science. 297:2002;400-403 In this study, the authors explore the neural underpinnings of the apparent relationship between polymorphism in the 5-HTT promoter and emotional behavior. Using BOLD fMRI, the authors demonstrate an increased amygdala response to emotionally laden stimuli in subjects carrying the less efficient s allele, presumably with greater synaptic serotonin availability, in comparison to subjects homozygous for the l allele. These findings suggest that the increased anxiety and fear reportedly associated with s carriers might be a consequence of hyper-responsiveness of the amygdala to relevant environmental stimuli.
35. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 274:1996;1527-1531.
36. Collier D.A., Stober G., Li T., Heils A., Catalano M., Di Bella D., Arranz M.J., Murray R.M., Vallada H.P., Bengel D.et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry. 1:1996;453-460.
37. Heinz A., Jones D.W., Mazzanti C., Goldman D., Ragan P., Hommer D., Linnoila M., Weinberger D.R. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry. 47:2000;643-649.
38. Willeit M., Stastny J., Pirker W., Praschak-Rieder N., Neumeister A., Asenbaum S., Tauscher J., Fuchs K., Sieghart W., Hornik K.et al. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry. 50:2001;8-12.
39. Shioe K., Ichimiya T., Suhara T., Takano A., Sudo Y., Yasuno F., Hirano M., Shinohara M., Kagami M., Okubo Y.et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse. 48:2003;184-188.
40. Poo M.M. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2:2001;24-32.
41. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M.et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 112:2003;257-269 The authors present converging evidence from both in vitro and in vivo approaches to illustrate the role of BDNF in human memory and hippocampal function. In healthy human volunteers, they demonstrate that the met allele of the BDNF polymorphism is associated with decreased N-acetyl aspartate, a putative marker of neuronal integrity and synaptic abundance, and deficits in episodic memory. Using cultured rat hippocampal neurons transfected with the val and met alleles of BDNF, they illustrate that the deleterious effects of the met allele result from abnormal intracellular trafficking and regulated secretion of BDNF. A unique aspect of this study is that it presents converging evidence from in vitro, in vivo and behavioral measures to show how differences in gene and protein structure manifest in differences in cellular mechanisms, which eventually lead to differences in physiological and behavioral measures.
42. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J.et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
43. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
44. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 334:1996;752-758.
45. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L.et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 97:2000;6037-6042.
46. Smith J.D., Sikes J., Levin J.A. Human apolipoprotein E allele-specific brain expressing transgenic mice. Neurobiol Aging. 19:1998;407-413.
47. Bookheimer S.Y., Strojwas M.H., Cohen M.S., Saunders A.M., Pericak-Vance M.A., Mazziotta J.C., Small G.W. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 343:2000;450-456.
48. Petrella J.R., Lustig C., Bucher L.A., Jha A.P., Doraiswamy P.M. Prefrontal activation patterns in subjects at risk for Alzheimer disease. Am J Geriatr Psychiatry. 10:2002;112-113.
49. Burggren A.C., Small G.W., Sabb F.W., Bookheimer S.Y. Specificity of brain activation patterns in people at genetic risk for Alzheimer disease. Am J Geriatr Psychiatry. 10:2002;44-51.
50. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Haardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 101:2004;284-289.
51. Cohen R.M., Podruchny T.A., Bokde A.L., Carson R.E., Herscovitch P., Kiesewetter D.O., Eckelman W.C., Sunderland T. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon4 allele. Synapse. 49:2003;150-156.
52. Small G.W., Agdeppa E.D., Kepe V., Satyamurthy N., Huang S.C., Barrio J.R. In vivo brain imaging of tangle burden in humans. J Mol Neurosci. 19:2002;323-327.
53. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C.et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 10:2002;24-35.